ESMO 2021 | First-line treatment decision making for patients with RCC
Guillermo De Velasco
• 27 Sep 2021
Guillermo De Velasco, MD, PhD, University Hospital 12 de Octubre, Madrid, Spain, discusses first-line treatment approaches for patients with cell renal cell carcinoma (RCC). A large number of treatment options represents a major challenge for clinicians because there are more factors to consider, and there is not enough data comparing different clinical trials. Dr De Velasco gives double immune checkpoint blockade therapy versus tyrosine kinase inhibitor (TKI) plus immunotherapy as an example and explains that treatment choices should be based on safety profiles. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
